China’s growth continues as country becomes clinical trial powerhouse
As China’s powerhouse status grows even bigger in the clinical trial space, industry leaders are set to come together to …
Post
-
-
Context drops bispecific T-cell engager on cost-cutting initiative
Philadelphia-based biotech Context Therapeutics has terminated the development programme for one of its pipeline bispecific T-cell engagers (BiTEs) as the …
-
BioVie stock sinks on Phase IIb Parkinson’s trial data
BioVie’s stock crashed after the biotech released data from its Phase IIb Parkinson’s disease trial that used a unique composite …
-
DSMB approves dose escalation in PepGen’s FREEDOM2-DM1 study
PepGen has announced that an independent Data and Safety Monitoring Board (DSMB) has approved the progression to the highest dosage …
-
First patient dosed with DISP-10 in Dispatch Bio’s cancer trial
Dispatch Bio has dosed the first participant in a Phase I clinical trial aimed at evaluating the efficacy and safety …
-
Context drops bispecific T-cell engager on cost-cutting initiative
Philadelphia-based biotech Context Therapeutics has terminated the development programme for one of its pipeline bispecific T-cell engagers (BiTEs) as the …
-
BioVie stock sinks on Phase IIb Parkinson’s trial data
BioVie’s stock crashed after the biotech released data from its Phase IIb Parkinson’s disease trial that used a unique composite …
-
DSMB approves dose escalation in PepGen’s FREEDOM2-DM1 study
PepGen has announced that an independent Data and Safety Monitoring Board (DSMB) has approved the progression to the highest dosage …
-
First patient dosed with DISP-10 in Dispatch Bio’s cancer trial
Dispatch Bio has dosed the first participant in a Phase I clinical trial aimed at evaluating the efficacy and safety …
-
Moderna kicks off Phase I Ebola trial as Africa readies itself for research
Moderna has initiated a Phase I trial of its mRNA Ebola vaccine for the Bundibugyo variant, just as Africa is …
-
MSD and Gilead scrap Phase III Trodelvy-Keytruda study on lacklustre interim data
MSD (Merck & Co) and Gilead Sciences have terminated a Phase III trial evaluating a duo of blockbuster oncology medicines …
-
Summit Therapeutics begins Phase II/III HARMONi-GU1 study of ivonescimab
Summit Therapeutics has expanded its clinical programme for ivonescimab with the Phase II/III HARMONi-GU1 study to assess its use in …
-
China-ready by design: Leveraging NMPA’s new 30‑working day IND pathway
Over the last decade, China has become a key destination for oncology clinical trials, with Chinese sites increasingly incorporated within …
-
SystImmune doses first patient in Phase III trial for ES-SCLC
SystImmune has dosed the first patient in its global Phase III clinical trial, BrenDeLL-Lung01, assessing BL-M14D1 combined with atezolizumab in …
-
What is ‘Premium Content’ on Clinical Trials Arena?
Clinical Trials Arena has introduced new ‘Premium Content’ for its readers – here’s an explanation of what’s changing and what …
